23andMe Holding Co. (ME)
After hours:
| Previous close | 2.4000 |
| Open | 2.3800 |
| Bid | 2.4500 x 1400 |
| Ask | 2.4700 x 2200 |
| Day's range | 2.3300 - 2.5000 |
| 52-week range | 2.1200 - 13.6800 |
| Volume | |
| Avg. volume | 3,655,503 |
| Market cap | 1.114B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Motley Fool
Why 23andMe Stock Was Lagging the Market Today
The stock market was experiencing a frothy Friday on the last trading day of the week, but 23andMe Holding (NASDAQ: ME) was a bit of a wallflower at the party. As of 1:30 p.m. ET , the genetic testing and research specialist's shares were up only incrementally, at a rate well behind the S&P 500 index's 1.7% gain. For 23andMe's fourth quarter of fiscal 2022, the company recorded just under $101 million in revenue, which was 14% higher than the same period of the previous year.
- Simply Wall St.
Investors one-year losses grow to 69% as the stock sheds US$72m this past week
Investing in stocks comes with the risk that the share price will fall. And unfortunately for 23andMe Holding Co...
- Motley Fool
23andMe CEO Anne Wojcicki on Bringing Health Information Directly to People
In this podcast, Motley Fool contributor Brian Orelli interviews Anne Wojcicki, the CEO of 23andMe (NASDAQ: ME), about her company and why it's looking to tell you much more than the names of your long-lost relatives. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. Anne Wojcicki: [MUSIC] When I think one of our legacies, hopefully, will be, is that 23andme has really proven that complicated information can go direct to a consumer, it does not have to have a one-to-one interaction with the physician.
